Scientists from the University of Cambridge, University of Edinburgh, and University College London have conducted the largest study of its kind, analyzing linked electronic health records of nearly 14 million children under 18 in England (representing 98% of the pediatric population) between January 2020 and December 2022.
Published in The Lancet Child & Adolescent Health, the research examined 3.9 million children diagnosed with COVID-19 and 3.4 million who received their first dose of the Pfizer-BioNTech vaccine. All data were de-identified and analyzed within NHS England’s secure data environment.
Key Findings: Risk Comparison
The study compared risks of rare complications following COVID-19 diagnosis versus vaccination:
Post-infection risks: Significantly higher for five conditions including arterial/venous thrombosis, thrombocytopenia, and myocarditis/pericarditis
Risk duration: Infection-related risks peaked within first 4 weeks and remained elevated for up to 12 months for some conditions
Vaccination risks: Only short-term (4-week) increase in myocarditis/pericarditis risk, which then returned to baseline levels
Quantitative Risk Assessment
Researchers calculated absolute risk differences over six months:
- COVID-19 infection caused 2.24 extra cases of myocarditis/pericarditis per 100,000 children
- Vaccination caused only 0.85 extra cases per 100,000 children
- Infection carried 2.6 times higher risk of heart inflammation complications compared to vaccination
Risk Duration and Patterns
The temporal patterns revealed crucial differences:
Infection-associated risks showed prolonged elevation (up to one year for some complications)
Vaccine-associated risks were transient and limited to the immediate post-vaccination period
Multiple complication types were associated with infection, while vaccination risk was primarily limited to cardiac inflammation
Expert Commentary and Public Health Implications
Professor Pia Hardelid from UCL and the NIHR Great Ormond Street Hospital Biomedical Research Centre stated: “Throughout the pandemic, families faced difficult choices. By building a stronger evidence base comparing both infection and vaccination outcomes, we hope to support decision-making based on the best available data.”
Professor Angela Wood from Cambridge University and Deputy Director of the BHF Data Science Centre added: “Using England’s comprehensive health records, we found risks following COVID-19 infection were both higher and more prolonged than post-vaccination. While vaccine-related risks remain rare and short-lived, infection risks may change with new variants.”
Research Significance and Limitations
Professor William Whiteley from University of Edinburgh noted: “Reliable information is essential for health decisions. Our study shows that during the pandemic, the risk of myocarditis and inflammatory conditions was low in children and young people, and was lower following vaccination than after COVID-19 infection.”
The authors acknowledge limitations including the evolving nature of variants and need for continued monitoring of booster effects. This research provides crucial evidence for global vaccination policies and pediatric COVID-19 management strategies.
Related topics:
